Recent News

• 05.01.2025 - Q1 2025 Amgen Earnings Conference Call
• 05.01.2025 - Q1 2025 Amgen Earnings Conference Call
• 04.25.2025 - AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO
• 04.25.2025 - AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO
• 04.11.2025 - IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
• 04.11.2025 - IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
• 04.03.2025 - UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
• 04.03.2025 - UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE

Recent Filings

• 04.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.17.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.16.2025 - PX14A6G Notice of exempt solicitation submitted by non-management
• 04.09.2025 - DEF 14A Other definitive proxy statements
• 04.09.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.02.2025 - ARS Annual Report to Security Holders
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities